435 related articles for article (PubMed ID: 9531046)
41. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
42. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
44. [Plasma haemostatic and fibrinolytic activities and their relationship to levels of serum lipids and apolipoproteins in endogenous hypertriglyceridemic patients].
Shen T; Bai H; Liu B; Liu Y; Zhang Z; Deng Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):405-8. PubMed ID: 12910674
[TBL] [Abstract][Full Text] [Related]
45. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
46. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
47. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
48. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
49. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis.
Kamper EF; Kopeikina LT; Trontzas P; Potamianou A; Tsiroglou E; Stavridis JC
J Rheumatol; 2000 Nov; 27(11):2545-50. PubMed ID: 11093432
[TBL] [Abstract][Full Text] [Related]
50. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
[TBL] [Abstract][Full Text] [Related]
51. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
[TBL] [Abstract][Full Text] [Related]
52. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity.
Väisänen S; Baumstark MW; Penttilä I; Bouchard C; Halonen P; Rankinen T; Berg A; Rauramaa R
Thromb Haemost; 1997 Dec; 78(6):1495-9. PubMed ID: 9423801
[TBL] [Abstract][Full Text] [Related]
53. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
54. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
55. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
56. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
57. Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system.
Hiraga T; Shimada M; Tsukada T; Murase T
Horm Metab Res; 1996 Nov; 28(11):603-6. PubMed ID: 8960902
[TBL] [Abstract][Full Text] [Related]
58. Plasminogen activator inhibitor (PAI) in obese men and obese women.
Cucuianu M; Lanczek M; Roman S
Rom J Intern Med; 1993; 31(3):183-92. PubMed ID: 8130756
[TBL] [Abstract][Full Text] [Related]
59. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
60. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass.
Chandler WL; Fitch JC; Wall MH; Verrier ED; Cochran RP; Soltow LO; Spiess D
Thromb Haemost; 1995 Nov; 74(5):1293-7. PubMed ID: 8607112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
